Arcellx, Inc.
DelistedCIK 1786205fmd_1SAEZDM83H9F0EGJ89J1V0SMAJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2021 to Dec 31, 2025, 20 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | – | 110 | 108 | 22 |
| Research and development | 47 | 150 | 134 | 157 | 158 |
| Total operating expenses | 65 | 191 | 200 | 246 | 275 |
| Operating income | (65) | (191) | (90) | (138) | (253) |
| Other non-operating income (expense) | 0 | 3 | 20 | 32 | 24 |
| Income before taxes | – | (189) | (70) | (105) | (229) |
| Income tax expense | 0 | 0 | 1 | 2 | 0 |
| Net income from continuing operations | – | (189) | (71) | (107) | (229) |
| Net income | (65) | (189) | (71) | (107) | (229) |